Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Mechanisms and Research Progress of Magnetic Nanoparticles in Modulating Neural Plasticity for Neuroregeneration

Liu Y., Zhang Y., Huang Y., Bi X.

Narrative Review on Neuroinflammation, published in Nanotechnol Sci Appl (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Nanotechnol Sci Appl (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41262679
PMCID
PMC12626030
DOI
10.2147/nsa.s546693
Citations
1

Abstract (original English)

Magnetic nanoparticles (MNPs), particularly those exhibiting superparamagnetism and biocompatibility, have garnered significant interest in the biomedical field due to their unique physicochemical properties. Recent studies have shown that MNPs can modulate neural plasticity by influencing key signaling pathways such as BDNF (Brain-Derived Neurotrophic Factor) and the PI3K/Akt pathway, critical for neuronal growth, synaptic connectivity, and functional recovery. This review provides a comprehensive analysis of the mechanisms through which MNPs interact with neural tissues, highlighting the diversity of nanoparticle types (eg, iron oxide, gold, and carbon-based nanoparticles) and their applications in neurodegenerative disease treatment and neural regeneration. Despite the immense potential of MNPs in neurodegenerative disease treatment, this review also compares them with traditional interventions, discussing their advantages and limitations. Additionally, it addresses key challenges, particularly the difficulty of overcoming the blood-brain barrier, and issues related to biocompatibility, toxicity, and long-term safety. In clinical applications, ethical concerns, such as patient informed consent and long-term risks, must also be considered alongside efficacy and safety. This review offers insights into these challenges and provides a framework for future research, aiming to ac

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research